Really appreciate that. You’re not alone. This wait has tested everyone’s conviction, even the most hardened longs. But to your question, why is it taking so long? Here’s how I see it.
The science has delivered. The Phase 3 results are published. The Pediatric Investigation Plan was approved in 2022 using the same matched external control methodology as the adult trial. That structure aligns with MHRA’s current real world evidence guidance, even though the formal ECA framework came later. We also know the UK Specials pathway has already been used for patient dosing. So this is no longer about proving DCVax-L works. This is about building a system that can carry it.
What’s likely happening is not a delay. It’s a controlled alignment. SI 87 changed the law in the UK. Flaskworks reached automation readiness. Advent scaled up manufacturing. DCVax-L is no longer being positioned as a one-site, one-country therapy. It’s being framed as a reproducible immunotherapy platform that can operate across borders. That changes everything.
This kind of transition doesn’t just need approval. It needs synchronization. Regulators. Manufacturers. Supply chain. Possibly even combination study frameworks and post-approval distribution channels. If the goal were just a GBM label, that could have been secured already. But if the aim is broader, if the platform is being positioned for global scale, then the timeline makes more sense.
And this is where Zavoico fits. Bosch gave it scientific foundation. Powers has kept it moving through walls. But the transition from trial to infrastructure needs a different type of discipline. Someone who knows how to bring platforms to scale, coordinate regulatory jurisdictions, manage timelines without breaking signal, and keep the entire system stable under silence. That’s Zavoico’s zone.
So yes, it’s been long. But not all silence is delay. Some silence means the system is being locked, so that when it moves, it doesn’t stop.
Bullish
AI
Market Data 
Markets 
